A number of SARS-CoV-2 variants have emerged from immunocompromised hosts, research has identified. It is thought that variants of concern—including B.1.1.7, a variant first identified in Kent, UK—were a result of long-term infection in people with a weakened immune system.
Severe cases of COVID-19 can involve extensive inflammation in the body, and clinicians have wondered if this state is similar to what are called cytokine storm syndromes, in which the immune system produces too many inflammatory signals that can sometimes lead to organ failure and death.
Data suggest that the messenger RNA-based COVID-19 vaccines developed by Pfizer-BioNTech and Moderna provide protection from infection for at least 6 months.
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease in late 2019 created an urgency to map its genome in an effort to diagnose and control the global threat.
COVID-19 has caused us to change the way we do business in every industry and performing laboratory audits is no exception. The challenge has been to perform quality laboratory accreditation audits in a world of social distancing and ever-changing travel restrictions.
One important and continuing trend in healthcare is the need for hospitals, nursing homes, and other medical providers to introduce effective antibiotic stewardship programs (ASPs).
Lack of interoperability between electronic health records (EHRs) has been a thorn in the side of healthcare providers—including clinical laboratorians and pathologists—who have to search multiple healthcare organizations’ databases to pull together medical records on individual patients.
Janus kinase inhibitors “may prove useful” in a wider range of immune-mediated inflammatory diseases, including refractory cutaneous dermatomyositis, chronic plaque psoriasis and other conditions, according to a speaker here.
We need your help to grow this newsletter! Please pass along the subscription link to any colleague you think would benefit from hearing about med lab news.